Results 261 to 270 of about 2,878,819 (307)
Some of the next articles are maybe not open access.
Molecular Immunology, 2015
This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e.
openaire +2 more sources
This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e.
openaire +2 more sources
Synthetic antibodies as therapeutics
Expert Opinion on Biological Therapy, 2006Synthetic antibody libraries, whose repertoires are designed, have advanced in the last decade to rival natural repertoire-based libraries. Many types of diversity design have been shown to generate highly functional libraries. Defined template and defined diversity in synthetic antibody libraries improve the process of discovering and optimizing new ...
openaire +2 more sources
Antibody and antibody derivatives as cancer therapeutics
WIREs Nanomedicine and Nanobiotechnology, 2019Antibodies are an important class of therapeutic for treating a wide range of diseases. These versatile macromolecules can be engineered to target many different antigens and to utilize several mechanisms of action to produce a pharmacological effect. The most common antibody platform used for therapeutics is immunoglobulin G (IgG). Advances in protein‐
Keith J, Arlotta, Shawn C, Owen
openaire +2 more sources
Therapeutic monoclonal antibodies
The Lancet, 2000The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully humanised mAb can now be made by recombinant engineering. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being ...
openaire +2 more sources
Recombinant therapeutic antibodies
Applied Microbiology and Biotechnology, 2007Recombinant antibody technology has revolutionized the development of antibody therapeutics. This minireview offers an overview of enabling technologies and future prospects of this rapidly progressing field.
openaire +2 more sources
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Expert Opinion on Biological Therapy, 2006Most of the existing therapeutic antibodies that have been licensed and developed as medical agents are of the human IgG1 isotype, the molecular weight of which is approximately 150 kDa. Human IgG1 is a glycoprotein bearing two N-linked biantennary complex-type oligosaccharides bound to the antibody constant region (Fc), in which the majority of the ...
Mitsuo, Satoh +2 more
openaire +2 more sources
The Expanding Role of Therapeutic Antibodies
International Reviews of Immunology, 2014Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine.
Simonetta Salemi +3 more
openaire +3 more sources
Antibody engineering for therapeutics
Current Opinion in Structural Biology, 2003With the acceptance of antibodies as therapeutics, a diversity of engineered antibody forms have been created to improve their efficacy, including enhancing the effector functions of full-length antibodies, delivering toxins to kill cells or cytokines in order to stimulate the immune system, and bispecific antibodies to target multiple receptors. After
openaire +2 more sources
Therapeutic Antibodies for Biodefense
2017Diseases can be caused naturally by biological agents such as bacteria, viruses and toxins (natural risk). However, such biological agents can be intentionally disseminated in the environment by a State (military context) or terrorists to cause diseases in a population or livestock, to destabilize a nation by creating a climate of terror, destabilizing
openaire +2 more sources
Expert Opinion on Biological Therapy, 2007
Recombinant monoclonal antibody (rMAb) therapy may be instituted to achieve one of two broad outcomes: i) killing of cells or organisms (e.g., cancer cells, bacteria); and ii) neutralisation of soluble molecules (e.g., cytokines in chronic disease or toxins in infection).
openaire +2 more sources
Recombinant monoclonal antibody (rMAb) therapy may be instituted to achieve one of two broad outcomes: i) killing of cells or organisms (e.g., cancer cells, bacteria); and ii) neutralisation of soluble molecules (e.g., cytokines in chronic disease or toxins in infection).
openaire +2 more sources